Viking Therapeutics, Genfit, Sagimet jump as Novo to buy Akero

3.75BUSD

See which Billionaires own this investment
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US92686J1060
CUSIP
92686J106
Sector
Healthcare
Industry
Biotechnology
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
-
PEG Ratio
-0.03
Book Value
5.57
Dividend Share
-
Dividend Yield
-
Earnings Share
-3.19
Wall Street Target Price
92.72
EPS Estimate Current Year
-3.74
EPS Estimate Next Year
-4.08
EPS Estimate Current Quarter
-0.9014
EPS Estimate Next Quarter
-0.9363
Most Recent Quarter
-
Revenue TTM
0
Gross Profit TTM
0
EBITDA
-
Profit Margin
0.00%
Return On Assets TTM
-30.28%
Return On Equity TTM
-47.34%
Revenue Per Share TTM
0
Qtly Revenue Growth YOY
0.00%
Diluted Eps TTM
-3.19
Qtly Earnings Growth YOY
0.00%
Trailing PE
0.00
Forward PE
0
Price Sales TTM
0
Price Book MRQ
5.8739
Enterprise Value Revenue
0
Enterprise Value EBITDA
-71
309.75
2.87%704.10
2.59%430.50
1.71%781.72
0.75%22.50
0.00%724.55
-7.23%22.22
-3.56%273.54
-0.74%90.00
-0.54%131.58
-0.29%Viking Therapeutics, Genfit, Sagimet jump as Novo to buy Akero
Viking Therapeutics is more than just a weight-loss stock, and that’s drawing cheers
Viking Therapeutics stock jumps after ‘great’ trial of weight-loss drug
Viking Therapeutics takes advantage of soaring stock price to issue fresh shares at a discount
Eli Lilly talks with Viking Therapeutics may have stalled - report
Viking Therapeutics gains amid renewed takeover speculation